

## SAFETY DATA SHEET

Pure & Conjugated Antibodies, Recombinant Proteins, Avidin, and Streptavidin

# SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product name : Pure & Conjugated Antibodies, Recombinant Proteins, Avidin, and Streptavidin

Product code : Not available.
Product type : Liquid.

Other means of identification

: Not available.

## 1.2 Relevant identified uses of the substance or mixture and uses advised against

Product use : Research.

Area of application : Industrial applications.

### **Uses advised against**

None identified.

## 1.3 Details of the supplier of the safety data sheet

BioLegend Inc. 8999 BioLegend Way San Diego, CA 92121 – USA

Tel: +1-858-455-9588 (7:00AM – 5:00PM PT, M-F) **e-mail address of person** : cs@biolegend.com

responsible for this SDS

## **Only representative**

BioLegend Inc. 4B Highgate Business Centre 33 Greenwood Place London, NW5 1LB - UK Tel: +44 (0) 20 3475 3880 http://www.biolegend.com/uk

## 1.4 Emergency telephone number

#### **National advisory body/Poison Centre**

Telephone number : Call 111 if you urgently need medical help or advice but it's not a life-threatening

situation (NHS 111 service).

NHS 111 is available 24 hours a day, 365 days a year

**Supplier** 

**Telephone number** : +44 (0) 20 3475 3880 (9:00AM - 5:00PM GMT, M-F)

## SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to UK CLP/GHS

Not classified.

The product is not classified as hazardous according to UK CLP Regulation SI 2019/720 as amended.

Date of issue/Date of revision : 08/09/2023 Date of previous issue : 19/07/2016 Version : 2 1/11

Pure & Conjugated Antibodies, Recombinant Proteins, Avidin, and Streptavidin

## SECTION 2: Hazards identification

Ingredients of unknown toxicity

1.4 percent of the mixture consists of component(s) of unknown acute oral toxicity 1.4 percent of the mixture consists of component(s) of unknown acute dermal

1.4 percent of the mixture consists of component(s) of unknown acute inhalation

toxicity

Ingredients of unknown

ecotoxicity

: Contains 1.4% of components with unknown hazards to the aquatic environment

See Section 11 for more detailed information on health effects and symptoms.

### 2.2 Label elements

Signal word : No signal word.

: No known significant effects or critical hazards. **Hazard statements** 

**Precautionary statements** 

**Prevention** : Not applicable. Response : Not applicable. **Storage** : Not applicable. : Not applicable. **Disposal** Supplemental label : Not applicable.

elements

**Annex XVII - Restrictions** : Not applicable.

on the manufacture. placing on the market and use of certain dangerous substances, mixtures and

articles

Special packaging requirements

Containers to be fitted with child-resistant

fastenings

: Not applicable.

: Not applicable. **Tactile warning of danger** 

## 2.3 Other hazards

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

Other hazards which do

: None known.

not result in classification

## **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures : Mixture

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Date of issue/Date of revision : 08/09/2023 : 19/07/2016 Version 2/11 Date of previous issue

Pure & Conjugated Antibodies, Recombinant Proteins, Avidin, and Streptavidin

## **SECTION 4: First aid measures**

### 4.1 Description of first aid measures

**Eye contact**: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower

eyelids. Check for and remove any contact lenses. Get medical attention if irritation

occurs.

Inhalation : Remove victim to fresh air and keep at rest in a position comfortable for breathing.

Get medical attention if symptoms occur.

Skin contact : Flush contaminated skin with plenty of water. Remove contaminated clothing and

shoes. Get medical attention if symptoms occur.

Ingestion : ₩ash out mouth with water. If material has been swallowed and the exposed

person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms

occur.

**Protection of first-aiders**: No action shall be taken involving any personal risk or without suitable training.

## 4.2 Most important symptoms and effects, both acute and delayed

## Over-exposure signs/symptoms

Eye contact : No specific data.

Inhalation : No specific data.

Skin contact : No specific data.

Ingestion : No specific data.

## 4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician : Treat symptomatically. Contact poison treatment specialist immediately if large

quantities have been ingested or inhaled.

**Specific treatments**: No specific treatment.

## **SECTION 5: Firefighting measures**

#### 5.1 Extinguishing media

Suitable extinguishing

media

: Use an extinguishing agent suitable for the surrounding fire.

**Unsuitable extinguishing** 

media

: Do not use water jet.

## 5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture

: **M** a fire or if heated, a pressure increase will occur and the container may burst.

Hazardous thermal decomposition products

: Decomposition products may include the following materials: phosphorus oxides

metal oxide/oxides carbon oxides

#### 5.3 Advice for firefighters

Special protective actions for fire-fighters

: Fromptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

Special protective equipment for fire-fighters

: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Date of issue/Date of revision : 08/09/2023 Date of previous issue : 19/07/2016 Version : 2 3/11

Pure & Conjugated Antibodies, Recombinant Proteins, Avidin, and Streptavidin

## SECTION 6: Accidental release measures

## 6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.

For emergency responders: Fispecialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

6.2 Environmental precautions

: Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

## 6.3 Methods and material for containment and cleaning up

**Small spill** 

: Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

Large spill

: Stop leak if without risk. Move containers from spill area. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with noncombustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations (see Section 13). Dispose of via a licensed waste disposal contractor. Note: see Section 1 for emergency contact information and Section 13 for waste disposal.

### 6.4 Reference to other sections

: See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

## SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 7.1 Precautions for safe handling

**Protective measures** Advice on general occupational hygiene

- : Put on appropriate personal protective equipment (see Section 8).
- : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

## 7.2 Conditions for safe storage, including any incompatibilities

store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

## 7.3 Specific end use(s)

Recommendations : Not available. **Industrial sector specific** : Not available. solutions

Date of issue/Date of revision : 08/09/2023 : 19/07/2016 Version : 2 Date of previous issue 4/11

Pure & Conjugated Antibodies, Recombinant Proteins, Avidin, and Streptavidin

## **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

### Occupational exposure limits

No exposure limit value known.

#### **Biological exposure indices**

None known.

Recommended monitoring procedures

: Reference should be made to appropriate monitoring standards. Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

#### **DNELs/DMELs**

No DNELs/DMELs available.

#### **PNECs**

No PNECs available

## 8.2 Exposure controls

Appropriate engineering controls

 Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

#### **Individual protection measures**

**Hygiene measures** 

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period.

Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

**Eye/face protection** 

: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

## **Skin protection**

**Hand protection** 

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

**Body protection** 

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Respiratory protection** 

: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

**Environmental exposure controls** 

: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Date of issue/Date of revision : 08/09/2023 Date of previous issue : 19/07/2016 Version : 2 5/11

Pure & Conjugated Antibodies, Recombinant Proteins, Avidin, and Streptavidin

## **SECTION 9: Physical and chemical properties**

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

#### 9.1 Information on basic physical and chemical properties

**Appearance** 

Physical state : Liquid.

**Colour** : Colourless. to Yellow.

Odour : Not available.
Odour threshold : Not available.
Melting point/freezing point : Not available.
Initial boiling point and : Not available.

boiling range

Flammability (solid, gas) : Not Flammable.

Lower and upper explosion : Not available.

limit

Flash point : Not available.

Auto-ignition temperature : Not available.

Decomposition temperature : Not available.

**pH** : 7.2

Viscosity : Not available.

Solubility(ies) : Not available.

Partition coefficient: n-octanol/ : Mot applicable.

water

Vapour pressure : Vapour Pressure at 20°C V

	Vapour Pressure at 20°C			Vapour pressure at 50°C		
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method
water	17.5	2.3		92.258	12.3	

Evaporation rate : Not available.

Relative density : Not available.

Vapour density : Not available.

Explosive properties : Not available.

Oxidising properties : Not available.

**Particle characteristics** 

Median particle size : Not applicable.

9.2 Other information

Physical/chemical properties : No additional information.

comments

## SECTION 10: Stability and reactivity

10.1 Reactivity : No specific test data related to reactivity available for this product or its ingredients.

10.2 Chemical stability : The product is stable.

**10.3 Possibility of**hazardous reactions
i: ✓ Inder normal conditions of storage and use, hazardous reactions will not occur.
Under normal conditions of storage and use, hazardous polymerisation will not

occur.

Date of issue/Date of revision : 08/09/2023 Date of previous issue : 19/07/2016 Version : 2 6/11

Pure & Conjugated Antibodies, Recombinant Proteins, Avidin, and Streptavidin

## SECTION 10: Stability and reactivity

10.4 Conditions to avoid : Feat

10.5 Incompatible materials : Mone known.

10.6 Hazardous decomposition products

: Under normal conditions of storage and use, hazardous decomposition products

should not be produced.

## **SECTION 11: Toxicological information**

## 11.1 Information on toxicological effects

**Acute toxicity** 

Conclusion/Summary : Not available.

**Acute toxicity estimates** 

N/A

**Irritation/Corrosion** 

**Conclusion/Summary**: Not available.

**Sensitisation** 

**Conclusion/Summary**: Not available.

**Mutagenicity** 

**Conclusion/Summary**: Not available.

**Carcinogenicity** 

Conclusion/Summary : Not available.

Reproductive toxicity

**Conclusion/Summary**: Not available.

**Teratogenicity** 

Conclusion/Summary: Not available.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Not available.

**Aspiration hazard** 

Not available.

**Information on likely routes**: Not available.

of exposure

Potential acute health effects

Eye contact
 Inhalation
 Skin contact
 Ingestion
 No known significant effects or critical hazards.
 Index in the first or critical hazards.

## Symptoms related to the physical, chemical and toxicological characteristics

Eye contact : No specific data.

Inhalation : No specific data.

Date of issue/Date of revision : 08/09/2023 Date of previous issue : 19/07/2016 Version : 2 7/11

Pure & Conjugated Antibodies, Recombinant Proteins, Avidin, and Streptavidin

## **SECTION 11: Toxicological information**

Skin contact : No specific data.

Ingestion : No specific data.

#### Delayed and immediate effects as well as chronic effects from short and long-term exposure

**Short term exposure** 

Potential immediate : Not available.

effects

Potential delayed effects : Not available.

**Long term exposure** 

Potential immediate : Not available.

effects

Potential delayed effects : Not available.

Potential chronic health effects

Not available.

**Conclusion/Summary**: Not available.

General : No known significant effects or critical hazards.

Carcinogenicity : No known significant effects or critical hazards.

Mutagenicity : No known significant effects or critical hazards.

Reproductive toxicity : No known significant effects or critical hazards.

Other information : Not available.

## **SECTION 12: Ecological information**

12.1 Toxicity

**Conclusion/Summary**: Not available.

12.2 Persistence and degradability

Conclusion/Summary : Not available.

12.3 Bioaccumulative potential

Not available.

12.4 Mobility in soil

Soil/water partition : Not available.

coefficient (Koc)

Mobility : Not available.

## 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

**12.6 Other adverse effects** : No known significant effects or critical hazards.

Date of issue/Date of revision : 08/09/2023 Date of previous issue : 19/07/2016 Version : 2 8/11

Pure & Conjugated Antibodies, Recombinant Proteins, Avidin, and Streptavidin

## **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

#### **Product**

**Methods of disposal** : The generation of waste should be avoided or minimised wherever possible.

Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities

with jurisdiction.

**Hazardous waste**: Within the present knowledge of the supplier, this product is not regarded as

hazardous waste, as defined by EU Directive 2008/98/EC.

**Packaging** 

packaging should be recycled. Incineration or landfill should only be considered

when recycling is not feasible.

Special precautions : This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and

runoff and contact with soil, waterways, drains and sewers.

## **SECTION 14: Transport information**

	ADR/RID	ADN	IMDG	IATA
14.1 UN number	Not regulated.	Not regulated.	Not regulated.	Not regulated.
14.2 UN proper shipping name	-	-	-	-
14.3 Transport hazard class(es)	-	-	-	-
14.4 Packing group	-	-	-	-
14.5 Environmental hazards	No.	No.	No.	No.

14.6 Special precautions for user

: **Transport within user's premises**: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in

the event of an accident or spillage.

14.7 Transport in bulk according to IMO instruments

: Not available.

## **SECTION 15: Regulatory information**

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture UK (GB)/REACH

Annex XIV - List of substances subject to authorisation

**Annex XIV** 

None of the components are listed.

Date of issue/Date of revision : 08/09/2023 Date of previous issue : 19/07/2016 Version : 2 9/11

Pure & Conjugated Antibodies, Recombinant Proteins, Avidin, and Streptavidin

## **SECTION 15: Regulatory information**

## Substances of very high concern

None of the components are listed.

## Ozone depleting substances

Not listed.

## **Prior Informed Consent (PIC)**

Not listed.

## **Persistent Organic Pollutants**

Not listed.

## Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

No listed substance

## **Seveso Directive**

his product is not controlled under the Seveso Directive.

### **EU regulations**

Industrial emissions : Not listed

(integrated pollution prevention and control) -

Air

Industrial emissions : Not listed

(integrated pollution prevention and control) -

Water

## **International regulations**

## Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

## **Montreal Protocol**

Not listed.

## **Stockholm Convention on Persistent Organic Pollutants**

Not listed.

## Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

## **UNECE Aarhus Protocol on POPs and Heavy Metals**

Not listed.

## 15.2 Chemical safety : This product contains substances for which Chemical Safety Assessments are still

assessment required.

## SECTION 16: Other information

Indicates information that has changed from previously issued version.

Date of issue/Date of revision : 08/09/2023 Date of previous issue : 19/07/2016 Version : 2 10/11

Pure & Conjugated Antibodies, Recombinant Proteins, Avidin, and Streptavidin

## **SECTION 16: Other information**

Abbreviations and acronyms

ATE = Acute Toxicity Estimate

GB CLP = UK CLP (EC No 1272/2008) on the Classification, Labelling and

Packaging of Substances and Mixtures as amended by (EU Exit) Regulations 2019

No. 720 and amendments

DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level

EUH statement = GB CLP-specific Hazard statement

N/A = Not available

PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number

SGG = Segregation Group

vPvB = Very Persistent and Very Bioaccumulative

## Procedure used to derive the classification

Not classified.

## Full text of abbreviated H statements

Not applicable.

#### **Full text of classifications**

Not applicable.

Date of issue/ Date of

revision

: 08/09/2023

Date of previous issue : 19/07/2016

Version : 2

## **Notice to reader**

To the best of our knowledge, the information contained herein is accurate. However, neither the abovenamed supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.

Date of issue/Date of revision : 08/09/2023 Date of previous issue : 19/07/2016 Version : 2 11/11